Tamoxifen Tales - Suggestions for Scientific Survival

Tamoxifen Tales: Suggestions for Scientific Survival presents a case study describing the academic journey of teams behind major advances in medical sciences, highlighting lessons learned that are applicable to the next generation of scientists. This book provides a manual on the successful mentoring of young scientists, including stories describing how training experience shaped careers to become leaders in academia and the pharmaceutical industry. The book documents Professor V. Craig Jordan's 50-year career in medical sciences that led to the discovery and development of Selective Estrogen Receptor Modulators (SERMs), which became the standard of women's healthcare around the world.
Additionally, it illustrates the versatility of a scientist with a commitment to serving societies. This important resource will be a useful and interesting book for established medical scientists, research mentors and advanced students wanting to chart a successful and impactful research career.

• Highlights lessons learned from the journey behind discovery science that are applicable to the scientific journey of the next generation of scientists
• Provides a manual on the successful mentoring of young scientists to become leaders in academia and the pharmaceutical industry
• Examines cancer treatment based on a personal determination to challenge at the frontiers of the science and to relate to personal life experience
• Includes references for further research reading

V. Craig Jordan is Professor of Breast Medical Oncology, Professor of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Previously, he was Scientific Director and Vice Chairman of Oncology at the Lombardi Comprehensive Cancer Center of Georgetown University. Jordan was the first to discover the breast cancer prevention properties of tamoxifen and the scientific principles for adjuvant therapy with antihormones. More recently his work has branched out into the prevention of multiple diseases in women with the discovery of the drug group, selective estrogen receptor modulator (SERMs). Currently, he plans to develop a new Hormone Replacement Therapy (HRT) for post-menopausal women that prevents breast cancer and does not increase the risk of breast cancer. In 2019 he was appointed Companion of the Most Distinguished Order of St. Michael and St. George by Queen Elizabeth II for services to women's health.